Colitis-Associated Colorectal Cancer in Patients with Inflammatory Bowel Diseases in a Tertiary Referral Center: A Propensity Score Matching Analysis.
colitis-associated colorectal cancer
colorectal cancer
inflammatory bowel diseases
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
07 Feb 2022
07 Feb 2022
Historique:
received:
01
12
2021
revised:
02
02
2022
accepted:
03
02
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Inflammatory bowel disease (IBD) is a risk factor in developing colitis-associated colorectal cancer (CA-CRC). CA-CRC causes the death of about 15% IBD patients and the risk is 1.5-2.4 fold higher among IBD sufferers than in the general population. The dysplasia CA-CRC develops in a different mechanism in comparison to sporadic colorectal cancer (CRC). This study aimed at evaluating the surgical treatment and its outcomes as well as 5-year survival rates in the CA-CRC and sporadic CRC patients. This single-center, retrospective, propensity score-matched case-control study was conducted with 2204 patients operated on due to primary CRC, who were hospitalized from 2003 to 2019. The CA-CRC group consisted of 49 patients with CRC in the course of IBD. The sporadic CRC group was selected with the propensity score matching technique and comprised 98 patients with sporadic CRC who did not have clinical or histopathological features characteristic for IBD. CA-CRC is characterized by a more aggressive clinical course. Surgical treatment of CA-CRC involves more palliative operations and is related with a higher risk of perioperative and postoperative complications. Further studies of CA-CRC risk factor stratification and the development of molecular markers hold promise in reducing CRC in IBD patients in the future were warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory bowel disease (IBD) is a risk factor in developing colitis-associated colorectal cancer (CA-CRC). CA-CRC causes the death of about 15% IBD patients and the risk is 1.5-2.4 fold higher among IBD sufferers than in the general population. The dysplasia CA-CRC develops in a different mechanism in comparison to sporadic colorectal cancer (CRC). This study aimed at evaluating the surgical treatment and its outcomes as well as 5-year survival rates in the CA-CRC and sporadic CRC patients.
MATERIALS AND METHODS
METHODS
This single-center, retrospective, propensity score-matched case-control study was conducted with 2204 patients operated on due to primary CRC, who were hospitalized from 2003 to 2019. The CA-CRC group consisted of 49 patients with CRC in the course of IBD. The sporadic CRC group was selected with the propensity score matching technique and comprised 98 patients with sporadic CRC who did not have clinical or histopathological features characteristic for IBD.
RESULTS
RESULTS
CA-CRC is characterized by a more aggressive clinical course. Surgical treatment of CA-CRC involves more palliative operations and is related with a higher risk of perioperative and postoperative complications. Further studies of CA-CRC risk factor stratification and the development of molecular markers hold promise in reducing CRC in IBD patients in the future were warranted.
Identifiants
pubmed: 35160321
pii: jcm11030866
doi: 10.3390/jcm11030866
pmc: PMC8836563
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Intest Res. 2014 Jul;12(3):194-204
pubmed: 25349593
Int J Colorectal Dis. 2018 Jul;33(7):963-966
pubmed: 29675590
Tech Coloproctol. 2019 Jan;23(1):3-13
pubmed: 30701345
J Surg Res. 2016 Jul;204(1):123-9
pubmed: 27451878
Clin Colorectal Cancer. 2017 Dec;16(4):293-299.e6
pubmed: 29033218
Oncotarget. 2015 Apr 30;6(12):9908-23
pubmed: 25839161
World J Gastroenterol. 2012 Aug 7;18(29):3839-48
pubmed: 22876036
Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:71-78
pubmed: 30060941
BMC Surg. 2017 Mar 21;17(1):28
pubmed: 28327112
World J Gastroenterol. 2014 Nov 28;20(44):16389-97
pubmed: 25469007
Gut. 2019 Jun;68(6):985-995
pubmed: 29991641
Ann Surg. 2021 Dec 14;:
pubmed: 34913897
Autoimmun Rev. 2010 Mar;9(5):A372-8
pubmed: 19903540
Dig Dis Sci. 2017 Aug;62(8):2126-2132
pubmed: 28050782
J Gastrointest Surg. 2013 May;17(5):981-90
pubmed: 23475629
Hered Cancer Clin Pract. 2019 Jul 12;17:18
pubmed: 31338130
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
Mucosal Immunol. 2011 Mar;4(2):239-44
pubmed: 20944558
World J Gastrointest Oncol. 2019 May 15;11(5):348-366
pubmed: 31139306
Semin Oncol. 2017 Feb;44(1):34-44
pubmed: 28395761
Clin Colorectal Cancer. 2016 Dec;15(4):e157-e163
pubmed: 27245559
Int J Mol Sci. 2020 Oct 24;21(21):
pubmed: 33114313
Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5
pubmed: 12950413
CA Cancer J Clin. 2009 Nov-Dec;59(6):366-78
pubmed: 19897840
World J Gastrointest Surg. 2019 May 27;11(5):261-270
pubmed: 31171957
J Crohns Colitis. 2020 Dec 2;14(12):1687-1692
pubmed: 32498084
Trends Mol Med. 2002 Jan;8(1):10-6
pubmed: 11796261
Curr Opin Gastroenterol. 2010 Sep;26(5):466-70
pubmed: 20664346
Clin Colorectal Cancer. 2020 Dec;19(4):e151-e156
pubmed: 32798155
Aliment Pharmacol Ther. 2006 Apr 15;23(8):1097-104
pubmed: 16611269
Gastrointest Endosc. 2017 Dec;86(6):962-971
pubmed: 28987547
J Surg Res. 2016 Oct;205(2):384-392
pubmed: 27664887
Curr Treat Options Oncol. 2017 Apr;18(4):23
pubmed: 28391421
World J Gastroenterol. 2016 May 28;22(20):4794-801
pubmed: 27239106
Colorectal Dis. 2015 Nov;17(11):943-53
pubmed: 25808496
Clin Colon Rectal Surg. 2018 May;31(3):168-178
pubmed: 29720903
J Crohns Colitis. 2021 Dec 13;:
pubmed: 34897426
J Dig Dis. 2017 Dec;18(12):684-690
pubmed: 29119678
Inflamm Bowel Dis. 2011 Mar;17(3):802-8
pubmed: 20848547
Am J Gastroenterol. 2018 Dec;113(12):1801-1809
pubmed: 30353058